Category
NEUROKININ ANTAGONISTS
NEUROKININ ANTAGONISTS
Consistent
Purity
Global-Ready
Molecules
Advanced
Manufacturing
Scalable
Production
Partnership
Support
Netupitant API has been developed by ASANA Pharmaceutical as part of its anti-emetic and neuroreceptor-targeted API portfolio. Netupitant API, listed under CAS number 290297-26-6, is a selective neurokinin-1 (NK1) receptor antagonist used in combination therapies to prevent chemotherapy-induced nausea and vomiting (CINV).
ASANA Pharmaceutical brings expertise in the development and manufacturing of high-purity neuroreceptor-targeting APIs such as Netupitant. With deep capabilities in complex molecule handling and CNS-related actives, ASANA ensures global compliance, precision formulation, and therapeutic consistency. Our facilities serve clients across North America, Europe, and Asia with a focus on quality and scalability.
ASANA Pharmaceutical works closely with formulation partners and clinical developers in the anti-emetic and oncology support space, combining regulatory knowledge and technical strength to advance NK1 receptor antagonist APIs. Netupitant [CAS No. 290297-26-6] is a selective neurokinin-1 antagonist used primarily in fixed-dose combinations to prevent chemotherapy-induced nausea and vomiting (CINV). It plays a critical role in supportive cancer care and is a key product in ASANA’s CNS-targeted API portfolio. As demand grows for more effective oncology support therapies, ASANA is committed to delivering
Netupitant API are available on public databases such as Wikipidia!